公开(公告)号：EP2614819A4

公开(公告)日：2014-04-23

申请号：EP11821346

申请日：2011-09-01

申请人： KM TRANSDERM ,  MEDRX CO LTD

发明人： AKAZAWA MITSUJI ,  YAMASAKI KEIKO

IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K47/06 ,  A61K47/32

CPC分类号： A61M35/00 ,  A61K9/7053

公开(公告)号：EP1946753A4

公开(公告)日：2009-05-13

申请号：EP06822405

申请日：2006-10-20

申请人： MEDRX CO LTD

发明人： ENDO MITSURU ,  HAMAMOTO HIDETOSHI ,  YAMASAKI KEIKO ,  MATSUMURA SUEKO

IPC分类号： A61K31/196 ,  A61K31/352 ,  A61K31/436 ,  A61K45/00 ,  A61K47/18 ,  A61P17/00 ,  A61P37/08

CPC分类号： A61K9/0014 ,  A61K9/06 ,  A61K31/196 ,  A61K31/352 ,  A61K31/436 ,  A61K47/18

摘要： Mast cell degranulation inhibitors having a carboxyl group have not been used as medicines for external application, because of their low transdermal permeatibility. If the inhibitors are administered through transdermal application, any adverse side effect on organs in the body which may be produced when administered via an oral route administration could be avoided. Further, some of the mast cell degranulation inhibitors have an extremely poor photostability. This contributes to the difficulty in the development of a medicine for external application comprising the inhibitor. The transdermal permeability and photostability of a mast cell degranulation inhibitor can be improved by using the inhibitor in the form of a salt with an organic amine. Thus, disclosed is a preparation for external application comprising a mast cell degranulation inhibitor. The mast cell degranulation inhibitor and a preparation comprising the mast cell degranulation inhibitor can be improved in photostability.

公开(公告)号：EP2471539B1

公开(公告)日：2017-05-03

申请号：EP10811413

申请日：2010-05-21

申请人： MEDRX CO LTD

发明人： YAMASAKI KEIKO ,  TANIMOTO TAKAHIRO

IPC分类号： A61K31/685 ,  A61K8/34 ,  A61K8/44 ,  A61K8/55 ,  A61K9/08 ,  A61K31/205 ,  A61K47/10 ,  A61K47/18 ,  A61K47/24 ,  A61P3/04

CPC分类号： A61K8/44 ,  A61K8/345 ,  A61K8/553 ,  A61K9/0014 ,  A61K31/205 ,  A61K31/685 ,  A61K45/06 ,  A61K47/10 ,  A61K47/183 ,  A61K47/24 ,  A61Q19/00 ,  A61K2300/00

公开(公告)号：EP1716868A4

公开(公告)日：2009-07-15

申请号：EP05704361

申请日：2005-01-27

申请人： MEDRX CO LTD

发明人： HAMAMOTO HIDETOSHI ,  ISHIBASHI MASAKI ,  MATSUMURA SUEKO ,  YAMASAKI KEIKO

IPC分类号： A61K45/08 ,  A61K9/06 ,  A61K9/12 ,  A61K9/70 ,  A61K31/407 ,  A61K47/18 ,  A61P29/00

CPC分类号： A61K9/0014 ,  A61K9/7053 ,  A61K9/7076 ,  A61K31/407

摘要： An anti-inflammatory analgesic for external use containing etodolac as NSAID, which is excellent not only in skin permeability but also in the penetration into tissues present in the portions deeper than the skin and the diffusion in the tissues and which can act directly on the muscles or joint tissues with inflammation or pain and is little irritant to the skin, more specifically, an anti-inflammatory analgesic characterized by containing etodolac and a local anesthetic.

公开(公告)号：EP1674088A4

公开(公告)日：2009-04-15

申请号：EP04792796

申请日：2004-10-15

申请人： MEDRX CO LTD ,  NIPPON SHINYAKU CO LTD

发明人： YOKOYAMA HIDEAKIRA ,  HIRATA AKIHIKO ,  HAMAMOTO HIDETOSHI ,  ISHIBASHI MASAKI ,  YAMASAKI KEIKO ,  FUJII TAKERU

IPC分类号： A61K31/155 ,  A61K9/00 ,  A61K9/06 ,  A61K47/02 ,  A61K47/04 ,  A61K47/20 ,  A61K47/36 ,  A61P3/10

CPC分类号： A61K47/02 ,  A61K9/0056 ,  A61K31/155 ,  A61K47/36

摘要： A jelly preparation containing biguanide medicine that at administration, suppresses bitterness and harsh taste and reduces discomfort, and that despite having stability, excels in medicine release in the gastrointestinal tract. There is provided a jelly preparation containing biguanide medicine characterized in that a biguanide medicine, an inorganic acid and a water soluble polymer are contained. By virtue of the particular action of the inorganic acid, the conflicting properties of excelling in jelly preparation stability and medicine release can be simultaneously realized.

公开(公告)号：EP2471539A4

公开(公告)日：2014-03-26

申请号：EP10811413

申请日：2010-05-21

申请人： MEDRX CO LTD

发明人： YAMASAKI KEIKO ,  TANIMOTO TAKAHIRO

IPC分类号： A61K31/685 ,  A61K8/34 ,  A61K8/44 ,  A61K8/55 ,  A61K9/08 ,  A61K31/205 ,  A61K47/10 ,  A61K47/18 ,  A61K47/24 ,  A61P3/04

CPC分类号： A61K8/44 ,  A61K8/345 ,  A61K8/553 ,  A61K9/0014 ,  A61K31/205 ,  A61K31/685 ,  A61K45/06 ,  A61K47/10 ,  A61K47/183 ,  A61K47/24 ,  A61Q19/00 ,  A61K2300/00

公开(公告)号：EP1488812A4

公开(公告)日：2006-05-03

申请号：EP03743551

申请日：2003-03-03

申请人： MEDRX CO LTD

发明人： YOKOYAMA HIDEAKIRA ,  HIRATA AKIHIKO ,  HAMAMOTO HIDETOSHI ,  YAMASAKI KEIKO ,  FUJII TAKERU

IPC分类号： A61K9/00 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/7048 ,  A61K47/04 ,  A61K47/36 ,  A61K9/08 ,  A61K47/02 ,  A61K47/32 ,  A61K47/34

CPC分类号： A61K9/0095 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/7048

摘要： It is intended to provide a liquid matrix for medicinal use in which a drug can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being a liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness, and gels in vivo so as to control the release speed, and liquid oral preparations using the same. Namely, a liquid matrix which is a liquid auxiliary facilitating the swallowing of a drug, characterized by containing a water-soluble polymer gelling under acidic conditions and the break stress of the gel being about 3.0x103 N/m2 or more. Liquid oral preparations having favorable slow release properties even though being a liquid.

公开(公告)号：EP3069712A4

公开(公告)日：2016-11-16

申请号：EP14862046

申请日：2014-11-17

申请人： MEDRX CO LTD

发明人： YAMASAKI KEIKO

IPC分类号： A61K9/10 ,  A61K31/343 ,  A61K47/10 ,  A61K47/18 ,  A61K47/24

CPC分类号： A61K47/24 ,  A61K9/0014 ,  A61K31/343 ,  A61K47/10 ,  A61K47/18

摘要： The present invention provides a transdermal absorptive liquid preparation in which a medicament or a salt thereof is colloidally dispersed in propylene glycol or a propylene glycol-containing solvent, whose transdermal permeability of the medicament is excellent, problem of skin irritation is reduced. The liquid formulation of the present invention has a mode of particle diameter at around 100nm, and an average particle size of 50 to 500 nm. The liquid formulation of the present invention makes marked improvement in the transdermal permeability by further containing an absorption promoter such as triethanolamine.

公开(公告)号：EP1782831A4

公开(公告)日：2009-12-02

申请号：EP05768591

申请日：2005-08-01

申请人： MEDRX CO LTD

发明人： ENDO MITSURU ,  YAMASAKI KEIKO ,  HAMAMOTO HIDETOSHI ,  MATSUMURA SUEKO ,  ISHIBASHI MASAKI

IPC分类号： A61K45/06 ,  A61K31/167 ,  A61K31/352

CPC分类号： A61K31/352 ,  A61K9/0014 ,  A61K31/167 ,  A61K45/06 ,  A61K47/06 ,  A61K47/10

公开(公告)号：EP1491185A4

公开(公告)日：2006-10-04

申请号：EP03708551

申请日：2003-03-12

申请人： MEDRX CO LTD ,  NIPPON SHINYAKU CO LTD

发明人： HAMAMOTO HIDETOSHI ,  YAMASAKI KEIKO ,  YOKOYAMA HIDEAKIRA ,  HIRATA AKIHIKO ,  FUJII TAKERU

IPC分类号： A61L15/60 ,  A61L26/00 ,  A61K9/06 ,  A61K47/30 ,  A61L15/22

CPC分类号： A61L26/008 ,  A61L15/60 ,  A61L26/0014 ,  A61L26/0066 ,  A61L2300/106 ,  A61L2300/404 ,  C08L33/02

摘要： It is intended to provide an external medicine for wounds which has nonconventional convenience in treating skin damages accompanied by a large amount of an exudation such as bedsore, skin ulcer and burn and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external medicine for wounds is characterized by containing a water-soluble polymer and a crosslinking agent and being in the form of a powder or an ointment. After absorbing an exudation, the medicine undergoes phase transition from a sol to a gel and thus exhibits effects of adsorbing and eliminating necrotic tissues and protecting the wound face. Subsequently, it can continuously absorb the exudation. After using, it can be easily separated substantially as a mass, thereby achieving high therapeutic effects and convenience.